# Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

> **NCT06465199** · PHASE1,PHASE2 · RECRUITING · sponsor: **Milton S. Hershey Medical Center** · enrollment: 289 (estimated)

## Conditions studied

- Atypical Teratoid/Rhabdoid Tumor
- Embryonal Tumor With Multilayered Rosettes
- Ewing Sarcoma
- Diffuse Intrinsic Pontine Glioma
- Osteosarcoma
- Neuroblastoma
- DIPG Brain Tumor

## Interventions

- **DRUG:** Eflornithine (DFMO)
- **DRUG:** AMXT 1501 Dicaprate

## Key facts

- **NCT ID:** NCT06465199
- **Lead sponsor:** Milton S. Hershey Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-28
- **Primary completion:** 2033-02
- **Final completion:** 2035-02
- **Target enrollment:** 289 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06465199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06465199, "Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06465199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*